Immune Monitoring on Sipuleucel-T

Completed

Conditions studied: Prostate Cancer

In brief

The purpose of this protocol is perform comprehensive immune monitoring studies in patients with castration-resistant prostate cancer receiving Sipuleucel-T in an effort to better understand the mechanism of action of this treatment.

Key facts

Study ID

NCT02237170

Run by

Icahn School of Medicine at Mount Sinai

People needed

36

Starts

2012-06-01

Expected to finish

2016-12-01

Last updated by the study team

2017-01-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years of age
• Written informed consent obtained
• Patients with castration-resistant prostate cancer who are initiating Sipuleucel-T as standard therapy
• No prior systemic chemotherapy for metastatic prostate cancer
• Hemoglobin > 9 mg/dl

You may not qualify if…

• Patients unable to understand the research protocol and/or provide informed consent

Where it is running

• Comprehensive Cancer Center of Nevada — Las Vegas, Nevada, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• Weill Cornell Medical College — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.